S27 Are patients with COPD more adherent to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with multiple-inhaler triple therapy in a real-world UK primary care treated population?

Dmg Halpin,E Gubba,R Wild,O Massey,V Banks,N Snowise,C Compton,Cf Vogelmeier,A Czira,As Ismaila,Kj Rothnie,T Tritton,R Sharma,R Wood

doi:10.1136/thorax-2021-btsabstracts.33

S27 Are patients with COPD more adherent to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with multiple-inhaler triple therapy in a real-world UK primary care treated population?

Dmg Halpin, E Gubba + Show 12 more

Open Access

https://doi.org/10.1136/thorax-2021-btsabstracts.33

Copy DOI

Journal: Thorax

Publication Date: Nov 1, 2021

Affiliation: GlaxoSmithKline (United Kingdom), Adelphi Group (United Kingdom), King's College London, University of Exeter, GlaxoSmithKline (United States)

#Fluticasone Furoate/umeclidinium/vilanterol #Multiple-inhaler Triple Therapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Background and ObjectivesTriple therapy with inhaled corticosteroid, long-acting muscarinic antagonist and long-acting β2-agonist (ICS/LAMA/LABA) is recommended for patients with COPD who continue to experience exacerbations on dual therapy (LAMA/LABA or...

Full Text